A Phase 3 interventional study of ZG006 and 5-fluorouracil, Calcium folinate and Irinotecan in Neuroendocrine Carcinoma, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.
Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 11th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 21 of the 26 other live ones, and was the 33rd registered.
172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.
Browse Carcinoma, Neuroendocrine studies →26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–80
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Sites in China
Ages 18–70
Hansoh BioMedical R&D Company · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 24 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 60 across 144 interventional studies indexed under Carcinoma, Neuroendocrine.
Median enrollment 80 across the 32 interventional studies, 120 across the 7 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 39 have an industry lead sponsor. The 10 most frequent:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 7 studies filed under Carcinoma, Neuroendocrine — fewer than ten, so there is no comparison to draw.
11 of the studies in Carcinoma, Neuroendocrine with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06070740Peking Union Medical College HospitalFirst- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | 2026-11-30 |
| NCT07911423Peking Union Medical College HospitalImmunotherapy in Neuroendocrine Carcinoma of the Cervix | 2026-12-01 |
| NCT07879339Peking Union Medical College HospitalMulti-omics Study of Cervical Neuroendocrine Carcinoma | 2026-12-01 |
| NCT06157827Nanjing Leads Biolabs Co.,LtdA Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | 2026-12-28 |
| NCT07014540Beijing GoBroad HospitalA Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZG006 Q2W
Biological: ZG006
Investigator-selected chemotherapy (such as FOLFIRI regimen)
Drug: 5-fluorouracil, Calcium folinate and Irinotecan
ZG006 will be administered as an intravenous (IV) infusion.
Drug pages: Fluorouracil · Leucovorin · Irinotecan
Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-Fluorouracil: 400 mg/m\^2 by intravenous infusion on Day 1; 5-Fluorouracil: 2400 mg/m\^2 by continuous intravenous infusion over 46 to 48 hours, once two weeks.
Also known as: FOLFIRI
Overall Survival(OS)
Duration from the date of initial treatment to the date of death due to any cause.
Time frame: up to approximately 4 years
Progression-free Survival (PFS) (RECIST1.1)
A duration from the date of initial treatment to disease progression or death of any cause.
Time frame: up to approximately 4 years
Start is estimated for Jul 2026; primary completion for Jun 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alveltamig
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →